Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard practice for DLBCL diagnosis and guides treatment decisions. High-throughput chromosome conformation capture (Hi-C) DNA sequencing is a next-generation sequencing-based technology to identify genome-wide rearrangements using a single assay. In this study, Hi-C sequencing was performed using FFPE tissues from 159 patients with DLBCL, and identified 746 cancer genes at or proximal to the rearrangement breakpoints with a total of 1903 occurrences. Focusing on clinically important rearrangements, Hi-C detected 102 rearrangements of MYC, BCL2, and/or BCL6 in 92 patients and revealed the fusion partners, including 25 rearrangements missed by FISH. Causes of FISH negative results included FISH-cryptic breakpoints, complex or faint FISH signals, low percentage of FISH positivity, and issues related to tissue fixation. Moreover, in 20 patients (12.6%), Hi-C sequencing detected 22 rearrangements characteristic of other lymphoma types, including CCND1 rearrangements that could lead to reclassification as mantle cell lymphoma. Survival analysis for genome-wide rearrangements using machine learning models identified MYC, PD-L1, CCND1, BCL2, NTRK1/PRCC, RRAS, and FANCE rearrangements with significant prognostic effects in the DLBCL cohort. In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
Authors
- Michael Møller (ORCID: https://orcid.org/0000-0003-2041-3630)
- Karen Dybkær (ORCID: https://orcid.org/0000-0003-2488-435X)
- Weina Chen (ORCID: https://orcid.org/0000-0001-5638-4371)
- Ken H. Young (ORCID: https://orcid.org/0000-0002-5755-8932)
- Govind Bhagat (ORCID: https://orcid.org/0000-0001-6250-048X)
- Kristin Sikkink (ORCID: https://orcid.org/0000-0002-0805-0622)
- Benjamin M. Parsons (ORCID: https://orcid.org/0000-0002-5634-2937)
- Xiaoxian Zhao
- Eric D. Hsi (ORCID: https://orcid.org/0000-0001-8623-4067)
- Alex Hastie (ORCID: https://orcid.org/0000-0001-5829-2649)
- Zijun Y. Xu‐Monette (ORCID: https://orcid.org/0000-0002-7615-3949)
- Leon Bernal‐Mizrachi (ORCID: https://orcid.org/0000-0001-9775-6688)
- Anthony D. Schmitt (ORCID: https://orcid.org/0000-0002-3818-1156)
- Carlo Visco (ORCID: https://orcid.org/0000-0003-2863-0883)
- Farzaneh Khajouei (ORCID: https://orcid.org/0000-0002-0148-9122)
- Bangchen Wang (ORCID: https://orcid.org/0000-0002-0942-7858)
- 吴得红
- April Chiu (ORCID: https://orcid.org/0000-0002-6431-2666)
- Zenggang Pan (ORCID: https://orcid.org/0000-0003-4537-3356)
- Youli Zu (ORCID: https://orcid.org/0000-0001-8574-9974)
- Wayne Tam (ORCID: https://orcid.org/0000-0003-4283-0005)
- Chang Wang (ORCID: https://orcid.org/0000-0002-3883-8920)
- Andrés J.M. Ferreri (ORCID: https://orcid.org/0000-0001-9606-6124)
- Yong Li (ORCID: https://orcid.org/0000-0001-8838-1714)
- Xin Cao (ORCID: https://orcid.org/0000-0003-1722-023X)
- William W.L. Choi
- Beibei Lv
- Santiago Montes-Moreno
- Shuna Yao
- Alexandar Tzankov
- Maurilio Ponzoni
- J Han JM van Krieken
Institutions
- University of Verona (IT)
- Atrium Health Wake Forest Baptist (US)
- Gundersen Health System (US)
- Mayo Clinic (US)
- Radboud University Nijmegen (NL)
- Emory University (US)
- Vita-Salute San Raffaele University (IT)
- Baylor College of Medicine (US)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- San Raffaele University of Rome (IT)
- Zhengzhou University (CN)
- Hospital Base (CL)
- Hong Kong Sanatorium and Hospital (HK)
- Piedmont Cancer Institute (US)
- Arima Genomics (United States) (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Methodist Hospital (US)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Duke Medical Center (US)
- Henan Cancer Hospital (CN)
- Saint Louis University (US)
- University of Colorado Anschutz Medical Campus (US)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-06-16
- DOI
- https://doi.org/10.1182/bloodadvances.2026019675
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00